Should you invest in... the biotech business?

IF YOU are an investor looking for a "frontier market", you do not have to stray far from home. For those research-based companies at the cutting edge of technological development will give you a rollercoaster ride for your money every bit as exciting, and fraught with risk, as any emerging market.

Chief among these high- risk enterprises are the biotechnology stocks, those companies whose raison d'etre is to develop new products and processes through biochemical research and whose success or failure is often dependent upon their ability to develop and market a single new drug.

"There are very few biotech stocks that we look at, because the companies are so tiny and it has been an awful subsector to be in," says Jeremy Batstone of NatWest Stockbrokers. "It is an unloved sector which has seen a lot of disappointments, the most high profile of which was British Biotech."

In contrast to the outperformance of their bigger counterparts in the pharmaceutical companies, the small biotech sector has been suffering. Mark Mathias, marketing director of Finsbury Asset management,says: "Biotech shares have been complete dogs for two years. There have been some celebrated cases of bad management, which led to a bad press for the sector, which has depressed sentiment."

Glenn Meyer of Pavilion Asset Management says: "You have to adopt a portfolio approach to the biotech sector. Investing in individual biotech companies should be left to the specialists."

Lesley Buckett of Hill Samuel Asset Management says: "They are mainly very small cap stocks. The private investor would have to buy a lot of them to make an impact and the best way would be to have a portfolio via something like an investment trust. People who specialise in looking only at these stocks get it wrong, so what chance does the individual have? You are dealing with `blue sky' research, and how do you know that these scientists are actually going to come up with anything?"

Jeremy Batstone adds: "The trouble with biotech stocks is that they have had their glory days. Two or three years ago, when British Biotech's `wonder drug' was starting trials, these stocks were racing away and standing on ridiculous multiples. But as they have no earnings you can't properly rate companies like that - British Biotech was almost in the FTSE 100 at one point and hadn't actually produced anything. Now you can really see the wood for the trees and there isn't much of either."

Lesley Buckett says: "Biotech stocks were very lowly rated, then got very highly rated very quickly, as things like British Biotech began to take off. The pharmaceutical sector is a large part of the market, but that is on the basis of three very large stocks. The biotech companies have become even smaller with the derating they have experienced over the past couple of years."

Much of the problems associated with the sector have stemmed from long lead time. Mark Mathias says: "The underlying businesses take cash at the outset, then there is a long period when nothing seems to be happening because they are in the laboratory coming up with the drugs. So there was no news coming out of the biotechs, then bad news because of British Biotech and other bad management situations. Now positive news is coming through."

Jeremy Batstone says: "A company will build up market expectation of finding a cure for cancer or whatever, then let you down in a big way when you find it doesn't work. It means taking giant leaps of faith." Lesley Buckett says: "Ratings have become more sensible and you are beginning to see the same sort of cycle you see in the US. But these companies burn cash at an enormous rate. They will all need refinancing at some point."

When it does work, the rewards can be enormous and the best evidence comes from America. Mathias adds: "Biotech companies make profits by doing deals. There are 21 biotech companies in the US representing a total of $1.5bn (pounds 940m) in profits and this figures is going to rise to $2.5bn by the end of 2000. And they are available on an average p/e of 25 times earnings, which is reasonable.Some companies, like Powderject Pharmaceuticals, have developed world-leading technologies, although in this case it is a delivery system rather than an actual drug. SkyePharma is a company with successful technology, as is Chiroscience."

Jeremy Batstone says: "You have to consider how they are going to sell these drugs. Have they got marketing power? Chiroscience had a deal with Zeneca to market a drug, then after the Zeneca-Astra dealChiroscience was out in the cold, because Astra had a similar drug and didn't want a third party involved."

News
Jeremy Paxman has admitted he is a 'one-nation Tory' and complained that Newsnight is made by idealistic '13-year-olds' who foolishly think they can 'change the world'.
peopleThe idea has been greeted enthusiastically by the party's MPs
News
Michael Buerk in the I'm A Celebrity jungle 2014
people
Voices
File: David Cameron offers a toast during a State Dinner in his honour March 14, 2012
voicesAnd nobody from Ukip said babies born to migrants should be classed as migrants, says Nigel Farage
Arts and Entertainment
Avatar grossed $2.8bn at the box office after its release in 2009
filmJames Cameron is excited
PROMOTED VIDEO
Arts and Entertainment
Stik on the crane as he completed the mural
art
News
Happy in his hat: Pharrell Williams
people
Arts and Entertainment
Stella Gibson is getting closer to catching her killer
tvReview: It's gripping edge-of-the-seat drama, so a curveball can be forgiven at such a late stage
News
Brazilian football legend Pele pictured in 2011
peopleFans had feared the worst when it was announced the Brazil legand was in a 'special care' unit
News
i100(More than you think)
Sport
Brendan Rodgers seems more stressed than ever before as Liverpool manager
FOOTBALLI like Rodgers as a manager but Liverpool seem to be going backwards not forwards this season
News
ebooksNow available in paperback
News
The Magna Carta
archaeologyContemporary account of historic signing discovered
News
Phyllis Dorothy James on stage during a reading of her book 'Death Comes to Pemberley' last year
peopleJohn Walsh pays tribute to PD James, who died today
Sport
Benjamin Stambouli celebrates his goal for Tottenham last night
FOOTBALL
Life and Style
Dishing it out: the head chef in ‘Ratatouille’
food + drinkShould UK restaurants follow suit?
News
peopleExclusive: Maryum and Hana Ali share their stories of the family man behind the boxing gloves
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Argyll Scott International: Service Desk Analyst

£20000 - £22000 per annum: Argyll Scott International: Service Desk Analyst Re...

Argyll Scott International: 2x Service Desk Analyst

£20000 - £22000 per annum: Argyll Scott International: Service Desk Analyst Re...

Recruitment Genius: Senior Execution Trader

£30000 - £250000 per annum: Recruitment Genius: A global Rolling Spot FX, Comm...

Citifocus Ltd: ACA - Financial Reporting

£Attractive Package: Citifocus Ltd: Chartered accountant (ACA or CPA), must be...

Day In a Page

Homeless Veterans Christmas Appeal: ‘We give them hope. They come to us when no one else can help’

Christmas Appeal

Meet the charity giving homeless veterans hope – and who they turn to when no one else can help
Should doctors and patients learn to plan humane, happier endings rather than trying to prolong life?

Is it always right to try to prolong life?

Most of us would prefer to die in our own beds, with our families beside us. But, as a GP, Margaret McCartney sees too many end their days in a medicalised battle
Thomas Cook's outgoing boss Harriet Green got by on four hours sleep a night - is that what it takes for women to get to the top?

What does it take for women to get to the top?

Thomas Cook's outgoing boss Harriet Green got by on four hours sleep a night and told women they had to do more if they wanted to get on
Christmas jumper craze: Inside the UK factory behind this year's multicultural must-have

Knitting pretty: British Christmas Jumpers

Simmy Richman visits Jack Masters, the company behind this year's multicultural must-have
French chefs have launched a campaign to end violence in kitchens - should British restaurants follow suit?

French chefs campaign against bullying

A group of top chefs signed a manifesto against violence in kitchens following the sacking of a chef at a Paris restaurant for scalding his kitchen assistant with a white-hot spoon
Radio 4 to broadcast 10-hour War and Peace on New Year's Day as Controller warns of cuts

Just what you need on a New Year hangover...

Radio 4 to broadcast 10-hour adaptation of War and Peace on first day of 2015
Cuba set to stage its first US musical in 50 years

Cuba to stage first US musical in 50 years

Claire Allfree finds out if the new production of Rent will hit the right note in Havana
Christmas 2014: 10 best educational toys

Learn and play: 10 best educational toys

Of course you want them to have fun, but even better if they can learn at the same time
Paul Scholes column: I like Brendan Rodgers as a manager but Liverpool seem to be going backwards not forwards this season

Paul Scholes column

I like Brendan Rodgers as a manager but Liverpool seem to be going backwards not forwards this season
Lewis Moody column: Stuart Lancaster has made all the right calls – now England must deliver

Lewis Moody: Lancaster has made all the right calls – now England must deliver

So what must the red-rose do differently? They have to take the points on offer 
Cameron, Miliband and Clegg join forces for Homeless Veterans campaign

Cameron, Miliband and Clegg join forces for Homeless Veterans campaign

It's in all our interests to look after servicemen and women who fall on hard times, say party leaders
Millionaire Sol Campbell wades into wealthy backlash against Labour's mansion tax

Sol Campbell cries foul at Labour's mansion tax

The former England defender joins Myleene Klass, Griff Rhys Jones and Melvyn Bragg in criticising proposals
Nicolas Sarkozy returns: The ex-President is preparing to fight for the leadership of France's main opposition party – but will he win big enough?

Sarkozy returns

The ex-President is preparing to fight for the leadership of France's main opposition party – but will he win big enough?
Is the criticism of Ed Miliband a coded form of anti-Semitism?

Is the criticism of Miliband anti-Semitic?

Attacks on the Labour leader have coalesced around a sense that he is different, weird, a man apart. But is the criticism more sinister?
Ouija boards are the must-have gift this Christmas, fuelled by a schlock horror film

Ouija boards are the must-have festive gift

Simon Usborne explores the appeal - and mysteries - of a century-old parlour game